Literature DB >> 20025568

Integrins in bone metastasis formation and potential therapeutic implications.

P Clëzardin1.   

Abstract

Integrins constitute a family of cell surface receptors that are heterodimers composed of noncovalently associated alpha and beta subunits. Integrins bind to extracellular matrix proteins and immunogobulin superfamily molecules. They exert a stringent control on cell migration, survival and proliferation. However, their expression and functions are often deregulated in cancer, and many lines of evidence implicate them as key regulators during progression from primary tumor growth to metastasis. Here, we review the role of integrins in bone metastasis formation and present evidence that the use of integrin-targeted therapeutic agents may be an efficient strategy to block tumor metastasis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20025568     DOI: 10.2174/156800909789760348

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  15 in total

1.  [Effect of zoledronate on the osteoclast adhesion and gene expression of integrin α(v) and β3].

Authors:  Lin Jueshan; Dong Wei; Xu Chunfeng; Sun Hong; Feng Xiaojie; Qi Mengchun
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2014-12

2.  Down-regulation of β3-integrin inhibits bone metastasis of small cell lung cancer.

Authors:  Na Li; Jian-ping Zhang; Shan Guo; Jie Min; Li-li Liu; Hai-chuan Su; Ying-ming Feng; He-long Zhang
Journal:  Mol Biol Rep       Date:  2011-06-16       Impact factor: 2.316

Review 3.  Metastatic bone disease: role of transcription factors and future targets.

Authors:  Jitesh Pratap; Jane B Lian; Gary S Stein
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

Review 4.  Integrins and bone metastasis: integrating tumor cell and stromal cell interactions.

Authors:  Jochen G Schneider; Sarah R Amend; Katherine N Weilbaecher
Journal:  Bone       Date:  2010-09-17       Impact factor: 4.398

Review 5.  Tumour-derived miRNAs and bone metastasis.

Authors:  Martine Croset; Casina Kan; Philippe Clézardin
Journal:  Bonekey Rep       Date:  2015-05-13

Review 6.  Cancer to bone: a fatal attraction.

Authors:  Katherine N Weilbaecher; Theresa A Guise; Laurie K McCauley
Journal:  Nat Rev Cancer       Date:  2011-05-19       Impact factor: 60.716

7.  Synthesis and evaluation of a new bifunctional NETA chelate for molecular targeted radiotherapy using(90)Y or(177)Lu.

Authors:  Chi Soo Kang; Yunwei Chen; Hyunbeom Lee; Dijie Liu; Xiang Sun; Junghun Kweon; Michael R Lewis; Hyun-Soon Chong
Journal:  Nucl Med Biol       Date:  2014-10-20       Impact factor: 2.408

8.  Cilengitide affects tumor compartment, vascularization and microenvironment in experimental bone metastases as shown by longitudinal ¹⁸F-FDG PET and gene expression analysis.

Authors:  Maren Bretschi; Caixia Cheng; Hendrik Witt; Antonia Dimitrakopoulou-Strauss; Ludwig G Strauss; Wolfhard Semmler; Tobias Bäuerle
Journal:  J Cancer Res Clin Oncol       Date:  2012-12-11       Impact factor: 4.553

9.  Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.

Authors:  Lucas Novaes Teixeira; Larissa Moreira Spinola de Castro Raucci; Gabriela Caroline Alonso; Ricardo Della Coletta; Adalberto Luiz Rosa; Paulo Tambasco de Oliveira
Journal:  Tumour Biol       Date:  2016-06-16

Review 10.  Therapeutic targets for bone metastases in breast cancer.

Authors:  Philippe Clézardin
Journal:  Breast Cancer Res       Date:  2011-04-06       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.